Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.64 |
| ▸ | ITK | Q08881 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | TEC | P42680 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | CDK14 | O94921 | 1/20 | 0.47 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.47 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24150242 | 1.00 | BTK (0.64) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL12965715 | 0.78 | BTK (1.00) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL30190974 | 0.77 | BTK (0.57) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL24150640 | 0.77 | BTK (0.57) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL23721798 | 0.73 | AURKA (0.69) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL19202348 | 0.72 | BTK (0.54) | BTKEGFRMAP2K7JAK3AURKA | |
| SCHEMBL12813173 | 0.72 | BTK (1.00) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL24150532 | 0.71 | BTK (0.69) | BTKITKEGFRMAP2K7JAK3 | |
| SCHEMBL16176428 | 0.71 | CDK8 (0.71) | BTKITKJAK3PLCG1 | |
| SCHEMBL16176321 | 0.71 | BTK (1.00) | BTKITKPLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | BTK 4194/4885ITK 4359/4885EGFR 888/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | BTK 4194/4885ITK 4359/4885EGFR 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.